

Correction

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Maryam Zanjirband¹, Nicola Curtin¹, Richard J. Edmondson² and John Lunec¹

¹Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom

²Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom

Published: February 22, 2024

Copyright: © 2024 Zanjirband et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5, the actin band in the A2780 column contains a partial duplicate of the same band in the IGROV-1 column. The corrected Figure 5, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:69779–69796. <https://doi.org/10.18632/oncotarget.19266>




Figure 5: Combination of Nutlin-3/RG7388 with rucaparib increased upregulation of *TP53* downstream target, PUMA compared to rucaparib on its own but not compared to Nutlin-3/RG7388. Total levels of PUMA 24 hours after the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with rucaparib at constant 1:1 ratios of 1X their respective GI_{50} concentration analyzed by western blot in three wild-type *TP53* ovarian cancer cell lines.